Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × Docetaxel

BACKGROUND: Today, more than 70% of patients with primary node-negative breast cancer are cured by local therapy alone. Many patients receive overtreatment by adjuvant chemotherapy due to inadequate risk assessment. So far, few clinical trials have prospectively evaluated tumor biology based prognos...

Descripción completa

Detalles Bibliográficos
Autores principales: Kantelhardt, Eva J, Vetter, Martina, Schmidt, Marcus, Veyret, Corinne, Augustin, Doris, Hanf, Volker, Meisner, Christoph, Paepke, Daniela, Schmitt, Manfred, Sweep, Fred, von Minckwitz, Gunter, Martin, Pierre-Marie, Jaenicke, Fritz, Thomssen, Christoph, Harbeck, Nadia
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3089797/
https://www.ncbi.nlm.nih.gov/pubmed/21496284
http://dx.doi.org/10.1186/1471-2407-11-140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3089797/
https://www.ncbi.nlm.nih.gov/pubmed/21496284
http://dx.doi.org/10.1186/1471-2407-11-140

Ejemplares similares